The FDA recently warned that certain patients may more likely to experience a pulmonary embolism, or even die, while taking Xeljanz. Filing a Xeljanz lawsuit could allow these individuals, as well as their surviving loved ones, to obtain compensation for their injury-related damages.
The defective drug attorneys at Bernstein Liebhard LLP are now offering free, no-obligation legal reviews to victims of posible Xeljanz side effects, including:
To contact our office for more information about filing a Xeljanze lawsuit, please call (888) 994-5118 today.
The U.S. Food & Drug Administration (FDA) approved Xeljanz (tofactinib) in 2012. However, the agency only cleared the drug for patients with moderate to severe active RA who had not responded to methotrexate.
The FDA subsequently approved Xeljanz XR in 2016. Eventually, the agency would also expand tofactinib’s approved indications to include the treatment of psoriatic arthritis and ulcerative colitis.
European regulators refused to approve Xeljanz for RA in 2013, due to its potential to cause serious, opportunistic infections. Two years later, the FDA rejected Xeljanz as a treatment for moderate to severe plaque psoriasis.
When the FDA first approved Xeljanz, it ordered Pfizer to study the risk of heart-related events, cancer, and opportunistic infections at two doses (10 mg twice daily and 5 mg twice daily) in combination with methotrexate.
Subsequently, the company launched a post-marketing trial involving RA patients over the age of 50 treated with either:
In February 2019, the FDA disclosed that the trial’s most recent analysis suggested Xeljanz patients taking the 10 mg twice-daily dose were more likely to suffer pulmonary embolism (a blood clots in their lungs) or die compared to either those taking the lower dose or TNF inhibitors.
Apparently, the Xeljanz study won’t conclude until the end of 2019. The FDA, however, is working with Pfizer to evaluate other tofactinib safety data and will update the public when new information becomes available.
In the meantime, patients should understand that the FDA never approved the 10 mg twice-daily dose of Xeljanz to treat RA. In fact, that dosage is only indicated for ulcerative colitis patients.
Finally, tofacitinib patients should seek immediate medical attention for any unusual symptoms, including:
Filing a Xeljanz lawsuit may be the only way victims of these possible side effects can recover compensation for thei physical, financial, and emotional damages, such as:
Additionally, a Xeljanz lawsuit may allow surviving loved ones to recover compensation for:
To win a case, however, potential plaintiffs must prove that Pfizer knew (or should have known) that tofacitinib was unreasonably dangerous and failed to provide patients with adequate safety warnings.
Obviously, pursuing a Xeljanze lawsuit is a complex undertaking. If you want to succeed, you need the assistance of product liability attorneys with extensive experience litigating drug injury claims.
Bernstein Liebhard LLP has successfully represented hundreds of people seriously injured by dangerous drugs and medical devices.
If you are interested in filing a Xeljanz lawsuit, our Firm will represent you on contingency basis. This means your legal fees will be deducted from any judgment our attorneys win on your behalf, or any settlement we negotiate with Pfizer. However, you’ll owe absolutely nothing if your lawsuit is not successful.
All consultations are free, and you won’t be obligated to retain our Firm if you do speak with a member our legal team. To learn more about filing Xeljanz lawsuit, simply call our office today, at .
Get the latest news and litigation updates about this case by following us on Facebook. Click the "Like" button below.